Abstract
Three-week administration of sertraline or imipramine to rats (10 mg/kg, intraperitoneally, twice a day) increased ex vivo cyclic AMP-dependent protein kinase activity in the soluble but not in the particulate fraction of the frontal cortex. However, cyclic AMP-dependent protein kinase activity was not affected in either fraction of the parietotemporal cortex and hippocampus. Neither antidepressant altered protein kinase C activity in the soluble and particulate fractions or Ca2+/calmodulin-dependent protein kinase II activity in the frontal cortex. Therefore, sertraline and imipramine both selectively enhance cyclic AMP-dependent protein kinase activity in the frontal cortex. This enhancement might be involved in their biochemical mechanisms.
MeSH terms
-
1-Naphthylamine / analogs & derivatives*
-
1-Naphthylamine / pharmacology
-
Animals
-
Antidepressive Agents, Tricyclic / pharmacology*
-
Calcium-Calmodulin-Dependent Protein Kinase Type 2
-
Calcium-Calmodulin-Dependent Protein Kinases / metabolism
-
Cyclic AMP-Dependent Protein Kinases / metabolism
-
Hippocampus / drug effects
-
Hippocampus / enzymology
-
Imipramine / pharmacology*
-
Male
-
Parietal Lobe / drug effects
-
Parietal Lobe / enzymology
-
Prefrontal Cortex / drug effects
-
Prefrontal Cortex / enzymology*
-
Protein Kinase C / metabolism
-
Protein Kinases / metabolism*
-
Rats
-
Rats, Sprague-Dawley
-
Selective Serotonin Reuptake Inhibitors / pharmacology*
-
Sertraline
-
Temporal Lobe / drug effects
-
Temporal Lobe / enzymology
Substances
-
Antidepressive Agents, Tricyclic
-
Serotonin Uptake Inhibitors
-
1-Naphthylamine
-
Protein Kinases
-
Cyclic AMP-Dependent Protein Kinases
-
Protein Kinase C
-
Calcium-Calmodulin-Dependent Protein Kinase Type 2
-
Calcium-Calmodulin-Dependent Protein Kinases
-
Imipramine
-
Sertraline